SlideShare a Scribd company logo
1 of 7
Download to read offline
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease
GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global
immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five
European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of
therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology
data, until 2019.
The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome
(GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic
Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading
companies that could change the market landscape in the forecast period.
The report has been built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research
expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019
forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR)
of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease
awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the
disciplines that use the most immunoglobulins, while PI and CIDP are the top indications.
Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new
products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in
the US remains off-label for all other indications. Baxter, CSL Behring, and Grifols continue to command the
top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and
Europe will further boost market growth.
Scope
Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019 Analysis of
the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP Analysis of the
immunoglobulins markets in the leading global geographies: the US, the top five European countries, and
Japan Market characterization of the immunoglobulin market, covering size, revenue analysis by geography,
annual cost of therapy, and epidemiology Key drivers and barriers that have a significant impact on the market
Coverage of key marketed products, approved indications, and safety and efficacy profiles Coverage of the
pipeline molecules in various phases of drug development Competitive profiling of the leading companies:
Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma Key M&A activity and
licensing agreements between 2012 and mid-2013 in the global immunoglobulin market Overview of the
immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products
Reasons to Buy
Align your product portfolio to the markets with high growth potential Develop market-entry and
market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
for strong growth Develop key strategic initiatives by understanding the key focus areas of the leading
companies Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio
gaps
table Of Content
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
2 Immunoglobulins Market To 2019 - Introduction
2.1 Overview
3 Immunoglobulins Market To 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost Of Therapy
3.3 Immunoglobulins Market Drivers And Restraints
3.3.1 Market Drivers
3.3.2 Restraints
4 Immunoglobulins Market To 2019 - Geographical Landscape
4.1 Us
4.1.1 Revenue
4.1.2 Annual Cost Of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost Of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost Of Therapy
5 Immunoglobulins Market To 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions For Intravenous Immunoglobulin Usage - Us
5.1.2 Indications For Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines For Intravenous Immunoglobulin Usage - Uk
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
5.1.4 Indications For Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share For The Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost Of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost Of Therapy
5.4.4 Epidemiology
5.4.5 Current Use For Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost Of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost Of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost Of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost Of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost Of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation
6 Immunoglobulins Market To 2019 - Profiles Of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/d
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% Dif
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-c
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 Hyqvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy
7 Immunoglobulins Market To 2019 - Pipeline Analysis
7.1 Research And Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 Ivig3i Grifols 10%
7.2.2 Ri-002 (ivig)
8 Immunoglobulins Market To 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 Csl Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.a.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma Ag
8.6.1 Business Description
8.6.2 Recent Developments
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
9 Immunoglobulins Market To 2019 - M&a And Licensing Deals Landscape
9.1 M&a Deals
9.1.1 Grifols Buys 60% Of Progenika Biopharma
9.1.2 Grifols Acquires 40% Of The Capital Of Biotechnology Firm Vcn Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers In The Us From Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio With Acquisition Of Gambro
9.2 R&d Licensing Agreements
9.2.1 Baxter And Onconova Announce European Licensing Agreement For Anti-cancer Compound
Rigosertib
9.2.2 Baxter Announces Collaboration With Sanquin To Expand Capacity For Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership With Hemobras In Brazil
10 Immunoglobulins Market To 2019 - Asia-pacific And China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute For Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling
11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
11.5 Contact Us
11.6 Disclaimer
An online research report(http://www.onlineresearchreports.com/) is a one step solution to your market
research needs. We are engaged in the business of preparing the customized research reports on different
industries including food and beverages, pharmaceuticals, medical, and electronics among others.We have a
team of Research Analysts with complete understanding of the current market trends and major market
players. Our research reports are based on the requirements of our clients; however, we also prepare
syndicated research reports on emerging markets.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.onlineresearchreports.com/
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C

More Related Content

More from Ambikabasa

Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015Ambikabasa
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015Ambikabasa
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015Ambikabasa
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015Ambikabasa
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015Ambikabasa
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015Ambikabasa
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015Ambikabasa
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015Ambikabasa
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015Ambikabasa
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015Ambikabasa
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015Ambikabasa
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015Ambikabasa
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015Ambikabasa
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015Ambikabasa
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015Ambikabasa
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015Ambikabasa
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015Ambikabasa
 
Diarrhea pipeline review, h1 2015
Diarrhea   pipeline review, h1 2015Diarrhea   pipeline review, h1 2015
Diarrhea pipeline review, h1 2015Ambikabasa
 
Integra gen s.a (alint) product pipeline analysis, 2014 update
Integra gen s.a (alint)   product pipeline analysis, 2014 updateIntegra gen s.a (alint)   product pipeline analysis, 2014 update
Integra gen s.a (alint) product pipeline analysis, 2014 updateAmbikabasa
 
Exercise trends - us - october 2014
Exercise trends  - us - october 2014Exercise trends  - us - october 2014
Exercise trends - us - october 2014Ambikabasa
 

More from Ambikabasa (20)

Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015
 
Diarrhea pipeline review, h1 2015
Diarrhea   pipeline review, h1 2015Diarrhea   pipeline review, h1 2015
Diarrhea pipeline review, h1 2015
 
Integra gen s.a (alint) product pipeline analysis, 2014 update
Integra gen s.a (alint)   product pipeline analysis, 2014 updateIntegra gen s.a (alint)   product pipeline analysis, 2014 update
Integra gen s.a (alint) product pipeline analysis, 2014 update
 
Exercise trends - us - october 2014
Exercise trends  - us - october 2014Exercise trends  - us - october 2014
Exercise trends - us - october 2014
 

Recently uploaded

QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxQSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxDitasDelaCruz
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting
 
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR ESCORTS
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR  ESCORTSJAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR  ESCORTS
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR ESCORTSkajalroy875762
 
Call 7737669865 Vadodara Call Girls Service at your Door Step Available All Time
Call 7737669865 Vadodara Call Girls Service at your Door Step Available All TimeCall 7737669865 Vadodara Call Girls Service at your Door Step Available All Time
Call 7737669865 Vadodara Call Girls Service at your Door Step Available All Timegargpaaro
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingNauman Safdar
 
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165meghakumariji156
 
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfDr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfAdmir Softic
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPanhandleOilandGas
 
Berhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGBerhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGpr788182
 
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...NadhimTaha
 
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGParadip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGpr788182
 
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizharallensay1
 
Phases of Negotiation .pptx
 Phases of Negotiation .pptx Phases of Negotiation .pptx
Phases of Negotiation .pptxnandhinijagan9867
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSpanmisemningshen123
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwaitdaisycvs
 
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGBerhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGpr788182
 
UAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur Dubai
UAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur DubaiUAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur Dubai
UAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur Dubaijaehdlyzca
 
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTSDurg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTSkajalroy875762
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1kcpayne
 

Recently uploaded (20)

QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxQSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investors
 
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR ESCORTS
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR  ESCORTSJAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR  ESCORTS
JAJPUR CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN JAJPUR ESCORTS
 
Call 7737669865 Vadodara Call Girls Service at your Door Step Available All Time
Call 7737669865 Vadodara Call Girls Service at your Door Step Available All TimeCall 7737669865 Vadodara Call Girls Service at your Door Step Available All Time
Call 7737669865 Vadodara Call Girls Service at your Door Step Available All Time
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for Viewing
 
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165Lucknow Housewife Escorts  by Sexy Bhabhi Service 8250092165
Lucknow Housewife Escorts by Sexy Bhabhi Service 8250092165
 
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfDr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation Final
 
Berhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGBerhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur 70918*19311 CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
 
HomeRoots Pitch Deck | Investor Insights | April 2024
HomeRoots Pitch Deck | Investor Insights | April 2024HomeRoots Pitch Deck | Investor Insights | April 2024
HomeRoots Pitch Deck | Investor Insights | April 2024
 
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
 
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGParadip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
 
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
 
Phases of Negotiation .pptx
 Phases of Negotiation .pptx Phases of Negotiation .pptx
Phases of Negotiation .pptx
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
 
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGBerhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Berhampur CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
 
UAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur Dubai
UAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur DubaiUAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur Dubai
UAE Bur Dubai Call Girls ☏ 0564401582 Call Girl in Bur Dubai
 
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTSDurg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
Durg CALL GIRL ❤ 82729*64427❤ CALL GIRLS IN durg ESCORTS
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1
 

Immunoglobulins Market Size to 2019 Available on Researchmoz.us

  • 1. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019. The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the disciplines that use the most immunoglobulins, while PI and CIDP are the top indications. Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in the US remains off-label for all other indications. Baxter, CSL Behring, and Grifols continue to command the top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and Europe will further boost market growth. Scope Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019 Analysis of the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP Analysis of the immunoglobulins markets in the leading global geographies: the US, the top five European countries, and Japan Market characterization of the immunoglobulin market, covering size, revenue analysis by geography, annual cost of therapy, and epidemiology Key drivers and barriers that have a significant impact on the market Coverage of key marketed products, approved indications, and safety and efficacy profiles Coverage of the pipeline molecules in various phases of drug development Competitive profiling of the leading companies: Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma Key M&A activity and licensing agreements between 2012 and mid-2013 in the global immunoglobulin market Overview of the immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products Reasons to Buy Align your product portfolio to the markets with high growth potential Develop market-entry and market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 2. for strong growth Develop key strategic initiatives by understanding the key focus areas of the leading companies Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps table Of Content 1 Table Of Contents 1.1 List Of Tables 1.2 List Of Figures 2 Immunoglobulins Market To 2019 - Introduction 2.1 Overview 3 Immunoglobulins Market To 2019 - Market Overview 3.1 Revenue 3.2 Annual Cost Of Therapy 3.3 Immunoglobulins Market Drivers And Restraints 3.3.1 Market Drivers 3.3.2 Restraints 4 Immunoglobulins Market To 2019 - Geographical Landscape 4.1 Us 4.1.1 Revenue 4.1.2 Annual Cost Of Therapy 4.2 Top Five European Countries 4.2.1 Revenue 4.2.2 Annual Cost Of Therapy 4.3 Japan 4.3.1 Revenue 4.3.2 Annual Cost Of Therapy 5 Immunoglobulins Market To 2019 - Therapeutic Landscape 5.1 Main Therapeutic Indications 5.1.1 Indicated Conditions For Intravenous Immunoglobulin Usage - Us 5.1.2 Indications For Intravenous Immunoglobulin Usage - Europe 5.1.3 Guidelines For Intravenous Immunoglobulin Usage - Uk Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 3. 5.1.4 Indications For Intravenous Immunoglobulin Usage - Japan 5.2 Revenue Share For The Major Therapeutic Indications 5.3 Primary Immunodeficiency Market 5.3.1 Introduction 5.3.2 Revenue 5.3.3 Annual Cost Of Therapy 5.3.4 Epidemiology 5.3.5 Current Use 5.3.6 Geographical Segmentation 5.4 Guillain-barré Syndrome Market 5.4.1 Introduction 5.4.2 Revenue 5.4.3 Annual Cost Of Therapy 5.4.4 Epidemiology 5.4.5 Current Use For Therapies 5.4.6 Geographical Segmentation 5.5 Chronic Lymphocytic Leukemia Market 5.5.1 Introduction 5.5.2 Revenue 5.5.3 Annual Cost Of Therapy 5.5.4 Epidemiology 5.5.5 Current Use 5.5.6 Geographical Segmentation 5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market 5.6.1 Introduction 5.6.2 Revenue 5.6.3 Annual Cost Of Therapy 5.6.4 Epidemiology 5.6.5 Current Use 5.6.6 Geographical Segmentation 5.7 Myasthenia Gravis Market 5.7.1 Introduction 5.7.2 Revenue 5.7.3 Annual Cost Of Therapy 5.7.4 Epidemiology 5.7.5 Current Use 5.7.6 Geographical Segmentation 5.8 Multifocal Motor Neuropathy Market 5.8.1 Introduction 5.8.2 Revenue 5.8.3 Annual Cost Of Therapy 5.8.4 Epidemiology 5.8.5 Current Use Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 4. 5.8.6 Geographical Segmentation 5.9 Idiopathic Thrombocytopenic Purpura 5.9.1 Introduction 5.9.2 Revenue 5.9.3 Annual Cost Of Therapy 5.9.4 Epidemiology 5.9.5 Current Use 5.9.6 Geographical Segmentation 6 Immunoglobulins Market To 2019 - Profiles Of Marketed Products 6.1 Overview 6.2 Privigen 6.2.1 Overview 6.2.2 Approved Indications 6.2.3 Safety 6.2.4 Efficacy 6.3 Gammagard S/d 6.3.1 Overview 6.3.2 Approved Indications 6.3.3 Safety 6.3.4 Efficacy 6.4 Gammagard Liquid 6.4.1 Overview 6.4.2 Approved Indications 6.4.3 Safety 6.4.4 Efficacy 6.5 Octagam 5% 6.5.1 Overview 6.5.2 Approved Indications 6.5.3 Safety 6.5.4 Efficacy 6.6 Flebogamma 10% Dif 6.6.1 Overview 6.6.2 Approved Indications 6.6.3 Safety 6.6.4 Efficacy 6.7 Gamunex-c 6.7.1 Overview 6.7.2 Approved Indications 6.7.3 Safety 6.7.4 Efficacy 6.8 Gammaplex Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 5. 6.8.1 Overview 6.8.2 Approved Indications 6.8.3 Safety 6.8.4 Efficacy 6.9 Hyqvia 6.9.1 Overview 6.9.2 Approved Indications 6.9.3 Safety 6.9.4 Efficacy 6.10 Bivigam 6.10.1 Overview 6.10.2 Approved Indications 6.10.3 Safety 6.10.4 Efficacy 7 Immunoglobulins Market To 2019 - Pipeline Analysis 7.1 Research And Development Pipeline 7.2 Major Pipeline Product Profiles 7.2.1 Ivig3i Grifols 10% 7.2.2 Ri-002 (ivig) 8 Immunoglobulins Market To 2019 - Competitive Landscape 8.1 Baxter International Inc. 8.1.1 Business Description 8.1.2 Recent Developments 8.2 Biotest Pharmaceuticals 8.2.1 Business Description 8.2.2 Recent Developments 8.3 Bio Products Laboratory Ltd. 8.3.1 Business Description 8.3.2 Recent Developments 8.4 Csl Behring Limited 8.4.1 Business Description 8.4.2 Recent Developments 8.5 Grifols S.a. 8.5.1 Business Description 8.5.2 Recent Developments 8.6 Octapharma Ag 8.6.1 Business Description 8.6.2 Recent Developments Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 6. 9 Immunoglobulins Market To 2019 - M&a And Licensing Deals Landscape 9.1 M&a Deals 9.1.1 Grifols Buys 60% Of Progenika Biopharma 9.1.2 Grifols Acquires 40% Of The Capital Of Biotechnology Firm Vcn Bioscience 9.1.3 Grifols Purchases Three Plasma Donation Centers In The Us From Canada’s Cangene 9.1.4 Baxter Enhances Renal Therapies Portfolio With Acquisition Of Gambro 9.2 R&d Licensing Agreements 9.2.1 Baxter And Onconova Announce European Licensing Agreement For Anti-cancer Compound Rigosertib 9.2.2 Baxter Announces Collaboration With Sanquin To Expand Capacity For Plasma Therapies 9.2.3 Baxter Announces 20 Year Partnership With Hemobras In Brazil 10 Immunoglobulins Market To 2019 - Asia-pacific And China 10.1 India 10.1.1 Overview 10.1.2 Regulatory Landscape 10.1.3 National Institute For Biologicals 10.1.4 Marketed Products 10.1.5 Product Profiles 10.1.6 Company Profiling 10.2 China 10.2.1 Overview 10.2.2 Regulatory Information 10.2.3 Marketed Products 10.2.4 Company Profiling 10.3 Australia 10.3.1 Overview 10.3.2 Regulatory Landscape 10.3.3 Marketed Products 10.3.4 Product Profiles 10.3.5 Company Profiling 11 Global Immunoglobulins Market: Appendix 11.1 Market Definitions 11.2 Abbreviations 11.3 References 11.4 Research Methodology 11.4.1 Coverage 11.4.2 Secondary Research 11.4.3 Primary Research 11.4.4 Expert Panel Validation Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C
  • 7. 11.5 Contact Us 11.6 Disclaimer An online research report(http://www.onlineresearchreports.com/) is a one step solution to your market research needs. We are engaged in the business of preparing the customized research reports on different industries including food and beverages, pharmaceuticals, medical, and electronics among others.We have a team of Research Analysts with complete understanding of the current market trends and major market players. Our research reports are based on the requirements of our clients; however, we also prepare syndicated research reports on emerging markets. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.onlineresearchreports.com/ Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (C